Multiple Sclerosis
Conditions
Keywords
Multiple sclerosis, exoskeleton
Brief summary
The Hybrid Assistive Limb (HAL) exoskeleton detects bioelectrical signals from the muscles, responds to the intention of voluntary movement, and provides biological feedback. In this study, the effects of HAL application on walking performance and balance in patients with multiple sclerosis will be examined in a single-center, controlled design. Participants will undergo walking rehabilitation with HAL for 1 hour per day, 5 days a week, for a total of 2 months. Walking and balance performance will be assessed before and after the intervention using the 10-Minute Walk Test (10MWT) to measure maximum walking speed, the 6-Minute Walk Test (6MWT) to evaluate walking endurance and cardiorespiratory performance, and the Timed Up and Go Test (TUG) to assess functional mobility and dynamic balance. Additionally, walking parameters and static balance will be measured using Tecnobody systems. Appropriate statistical tests will be applied, and a significance level of p\<0.05 will be considered.
Detailed description
The Hybrid Assistive Limb (HAL) exoskeleton is a robotic device that detects bioelectrical signals from the muscles, responds to the user's intention to move voluntarily, and provides biological feedback to support motor function. This study aims to investigate the effects of HAL-assisted walking rehabilitation on walking performance and balance in patients with MS in a single-center, controlled design. Participants will undergo HAL-assisted walking rehabilitation for 1 hour per day, 5 days a week, over a period of 2 months. Assessments will be conducted before and after the intervention by trained clinicians and physiotherapists under standardized conditions. Walking and balance performance will be evaluated using the 10-Minute Walk Test (10MWT) to measure maximum walking speed, the 6-Minute Walk Test (6MWT) to assess walking endurance and cardiorespiratory performance, and the Timed Up and Go Test (TUG) to evaluate functional mobility and dynamic balance. Additionally, walking parameters-including step length, cadence, walking speed, joint range of motion of the hip, knee, and trunk, and gait symmetry-will be analyzed using the Tecnobody Walker View system, while static balance will be measured with the Tecnobody D-Wall system under eyes-open and eyes-closed conditions.
Interventions
Participants will receive walking rehabilitation with a lower extremity type Hybrid Assistive Limb (HAL) device, 5 days a week, 1 hour per day, for a total of 2 months.
Sponsors
Ege University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* No previous robotic rehabilitation. * Completion of the 10-meter walk test. * Mini mental status score ≥24. * MASS score \<2. * EDSS \<6.
Exclusion criteria
* History of serious degenerative disease. * Presence of open wounds. * History of thoracic surgery. * Chronic respiratory diseases. * Presence of unstable cardiovascular disease. * Medical conditions that prevent mobilization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 10-Meter Walk Test (10mWT) | Baseline (study start) and at 2 months. | 10-Meter Walk Test (10mWT): In this study, the 10-Meter Walk Test (10mWT) will be administered to assess walking speed. Participants will be asked to walk at a comfortable pace along the middle 10-meter section of a 14-meter walkway on level ground. |
| Timed Up and Go Test (TUG) | Baseline (study start) and at 2 months. | During the test, participants will be asked to rise from a 47 cm high chair with a backrest and armrests, walk a distance of 3 meters, return to the starting point by turning at a marked cone, and then sit back down in the chair. |
| 6-Minute Walk Test (6MWT) | Baseline (study start) and at 2 months. | The test will be performed in a straight 30-meter corridor, following the standard protocol established by the American Thoracic Society. |
| Balance performance assessed using the TecnoBody D-Wall system | Baseline (study start) and at 2 months. | Balance performance will be evaluated using the TecnoBody D-Wall device (TecnoBody Srl, Bergamo, Italy). The primary balance outcome will be the stability index score obtained from the system. Higher scores indicate better balance performance. |
| Stride Length Assessed by TecnoBody Walker View | Baseline and at 2 months | Stride length measured using the TecnoBody Walker View gait analysis system. |
| Walking Speed Assessed by TecnoBody Walker View | Baseline and at 2 months | Walking speed will be measured using the TecnoBody Walker View gait analysis system. Participants will walk at a comfortable pace along the walkway, and the average speed in meters per second will be recorded. |
| Double Support Time Assessed by TecnoBody Walker View | Baseline and at 2 months | Double support time, defined as the duration when both feet are in contact with the ground during gait, will be measured in seconds using the TecnoBody Walker View system. |
| Gait Symmetry Index Assessed by TecnoBody Walker View | Baseline and at 2 months | Gait symmetry will be assessed using the TecnoBody Walker View system by calculating the symmetry index from step length and stance duration for both legs, expressed as a percentage. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease severity assessed by the Expanded Disability Status Scale (EDSS) | Baseline (study start) and at 2 months. | Disease severity will be assessed using the Expanded Disability Status Scale (EDSS), a standardized and validated scale for patients with multiple sclerosis. The EDSS score ranges from 0 to 10, with higher scores indicating greater disability and worse clinical status. |
Countries
Turkey (Türkiye)
Outcome results
None listed